Infinity Pharmaceuticals purchased an option for $5 million to buy out all future potential royalty payments owed Millennium: The Takeda Oncology Company for sales in oncology of Infinity’s blood ...
shot up in the premarket session after its treatment for the blood cancer multiple myeloma was cleared by the FDA. The shares were recently up $1.65, or 13%, to $14.14. Millennium's proteasome ...
Julian Adams is the brain behind Millennium Pharmaceutical's MLN 341 drug, a drug that combats multiple myeloma, the second-most common blood cancer, representing 2 percent of all cancer deaths. Adams ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback